Age-related macular degeneration is responsible for an estimated 46% of cases of severe visual loss in adults over 40, and affects roughly 20 million U.S. adults aged 40 and older, including about 1.49 million with vision-threatening late-stage disease. Conversion from dry to wet AMD is time-sensitive: patients treated within 7 weeks of onset had a 38% rate of vision improvement at 6 months in one study, versus just 20% when treatment was delayed beyond 21 weeks. Because most early and intermediate AMD is asymptomatic and detected only on dilated exam, and wet-AMD conversion can be a same-day emergency, precise staging and documentation directly shape whether vision-preserving treatment arrives in time.
AAVBC's Adult Macular Degeneration Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering ICD-10 H35.31/H35.32 coding specificity by laterality, stage, and CNV activity, HCC 300 RAF mapping, dry-versus-wet AMD differentiation, OCT/OCTA/FAF diagnostic workup, geriatric risk factors and subtle early signs, MEAT documentation standards, and AAO PPP 2025-aligned treatment and referral pathways. Grounded in AAO guidance, this guide supports consistent, individualized clinical decision-making, helping care teams recognize wet-AMD conversion as a time-sensitive emergency and code disease stage and activity with the specificity risk adjustment requires, with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of adult macular degeneration — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
Age-related macular degeneration is responsible for an estimated 46% of cases of severe visual loss in adults over 40, and affects roughly 20 million U.S. adults aged 40 and older, including about 1.49 million with vision-threatening late-stage disease. Conversion from dry to wet AMD is time-sensitive: patients treated within 7 weeks of onset had a 38% rate of vision improvement at 6 months in one study, versus just 20% when treatment was delayed beyond 21 weeks. Because most early and intermediate AMD is asymptomatic and detected only on dilated exam, and wet-AMD conversion can be a same-day emergency, precise staging and documentation directly shape whether vision-preserving treatment arrives in time.
AAVBC's Adult Macular Degeneration Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering ICD-10 H35.31/H35.32 coding specificity by laterality, stage, and CNV activity, HCC 300 RAF mapping, dry-versus-wet AMD differentiation, OCT/OCTA/FAF diagnostic workup, geriatric risk factors and subtle early signs, MEAT documentation standards, and AAO PPP 2025-aligned treatment and referral pathways. Grounded in AAO guidance, this guide supports consistent, individualized clinical decision-making, helping care teams recognize wet-AMD conversion as a time-sensitive emergency and code disease stage and activity with the specificity risk adjustment requires, with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of adult macular degeneration — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
